To­tus pulls in $40M Se­ries A with sights on PI3Kα; FDA asks Sesen for an­oth­er tri­al af­ter CRL, biotech says

Af­ter spend­ing the last 18 months work­ing on iden­ti­fy­ing a lead can­cer drug, biotech start­up To­tus Med­i­cines has now raised $40 mil­lion in a Se­ries A round to get the ther­a­py head­ed to the clin­ic.

The biotech isn’t hold­ing any­thing back in its re­lease, tout­ing its “rev­o­lu­tion­ary” plat­form ap­proach and prospects in a high­ly com­pet­i­tive field. Their orig­i­nal tar­get is PI3Kα.

CEO Neil Dhawan says:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER